BACKGROUND. Pemetrexed-cisplatin chemotherapy is the standard of care in the

Size: px
Start display at page:

Download "BACKGROUND. Pemetrexed-cisplatin chemotherapy is the standard of care in the"

Transcription

1 1555 Gemcitabine and Vinorelbine in Pemetrexed-Pretreated Patients With Malignant Pleural Mesothelioma Paolo A. Zucali, MD 1 Giovanni L. Ceresoli, MD 1 Isabella Garassino, MD 1 Fabio De Vincenzo, MD 1 Raffaele Cavina, MD 1 Elisabetta Campagnoli, MD 1 Federico Cappuzzo, MD 1 Silvia Salamina, MD 1 Hector J. Soto Parra, MD 2 Armando Santoro, MD 1 1 Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy. 2 Department of Medical Oncology, Garibaldi- Nesima Hospital, Catania, Italy. BACKGROUND. Pemetrexed-cisplatin chemotherapy is the standard of care in the first-line treatment of unresectable malignant pleural mesothelioma (MPM). Second-line cytotoxic therapy is considered for a growing group of patients, but the optimal treatment has not been defined to date. Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM. METHODS. From January 2004 to September 2006, 30 consecutive patients who were pretreated with pemetrexed with or without a platinum-derivative were enrolled. Gemcitabine 1000 mg/m 2 and vinorelbine 25 mg/m 2 were administered intravenously on Days 1 and 8 every 3 weeks. Treatment was repeated for a maximum of 6 cycles or until progression or unacceptable toxicity. RESULTS. A partial response was observed in 3 patients (10%; 95% confidence interval [CI], %), and 10 patients (33.3%; 95% CI, %) had stable disease after treatment. Overall, 13 patients (43.3%; 95% CI, %) achieved disease control. The median time to progression was 2.8 months (range, months), and the median survival was 10.9 months (range, months). Hematologic toxicity was acceptable, with grade 3 or 4 neutropenia occurring in 11% of patients and thrombocytopenia occurring in 4% of patients; no case of febrile neutropenia was observed. Nonhematologic toxicity generally was mild. CONCLUSIONS. The gemcitabine and vinorelbine combination was moderately active and had an acceptable toxicity profile in pemetrexed-pretreated patients with MPM. The role of second-line treatment in MPM needs to be evaluated in prospective trials in large series of patients who are stratified according to previous treatment and prognostic factors. Cancer 2008;112: Ó 2008 American Cancer Society. Address for reprints: Polo A. Zucali, MD, Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano (Milan), Italy; Fax: (011) ; Received July 9, 2007; revision received September 20, 2007; accepted October 24, KEYWORDS: malignant pleural mesothelioma, second-line chemotherapy, pemetrexed-pretreated patients, gemcitabine-vinorelbine combination. Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor prognosis. Its incidence is increasing throughout most of the world, and it is predicted that it will rise in the next 10 to 20 years. 1 Most patients with MPM are not amenable to radical surgery, and systemic therapy is the only potential treatment option for the majority of patients. The combination of cisplatin (Platinol; Bristol-Myers Squibb, New York, NY) and pemetrexed (Alimta; Eli-Lilly and Company, Indianapolis, Ind) has recently become the standard of care in the first-line treatment of MPM. In fact, this combination significantly improved the response rate (RR), time to progression (TTP), overall survival (OS), and quality of life compared with cisplatin alone. 2 For patients who are unfit to receive a cisplatin-based chemotherapy, pemetrexed alone 3 or ª 2008 American Cancer Society DOI /cncr Published online 19 February 2008 in Wiley InterScience (www.interscience.wiley.com).

2 1556 CANCER April 1, 2008 / Volume 112 / Number 7 combined with carboplatin (Paraplatin; Bristol-Myers Squibb 4 ) has been proposed as an alternative treatment choice. The role of second-line chemotherapy in MPM is not yet established. Two small trials dedicated to second-line chemotherapy with the cisplatin analog ZD0473 (cis-amminedichloro [2 methylpyridine] platinum [II]; AstraZeneca Pharmaceuticals, Cheshire, United Kingdom) and with the combination of raltitrexed (Tomudex; AstraZeneca Pharmaceuticals) and oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) did not report efficacy but demonstrated the possibility of recruiting patients with good performance status to second-line studies. 5,6 In addition, case study reports and Phase II studies that included some pretreated patients have provided evidence that additional response is possible after second-line chemotherapy. 7 9 Recently, a noteworthy activity of pemetrexed, both alone and combined with carboplatin, as second-line treatment after prior platinumbased chemotherapy was reported. 10 In a randomized, multicenter Phase III study examining pemetrexed as second-line chemotherapy versus best supportive care (BSC), treatment with pemetrexed provided clinical benefit with a statistically significant improvement in TTP, whereas improvement in OS was not reported, possibly because of the influence of poststudy chemotherapy (PSC) on the BSC arm. 11 However, because pemetrexed-based regimens are being used increasingly in the first-line setting, 2,12 second-line chemotherapy should focus on other compounds in the future. Gemcitabine (Gemzar; Eli-Lilly and Company, Indianapolis, Ind) and vinorelbine (Navelbine; Pierre Fabre, Castres, France) have shown some activity as single agents or in combination in first-line treatment of MPM. Gemcitabine showed an activity as a single agent ranging from 0% to 31%, 13,20 and it is not known to be cross-resistant with pemetrexed. Moreover, as a single agent or in combination, gemcitabine was the most commonly used agent in PSC patients who were treated in the Phase III pemetrexed trial 21 and is considered 1 of most interesting drugs to explore in the second-line setting after pemetrexed-based chemotherapy. However, the cumulative cisplatin neurotoxicity and ototoxicity limit the enthusiasm for a cisplatin/gemcitabine combination approach in a second-line setting. 16,17 Alternatively, carboplatin and oxaliplatin 7,25,26 could be combined with gemcitabine. Vinorelbine is the only vinca alkaloid with proven single-agent activity in MPM. Treatment of 29 assessable MPM patients with weekly vinorelbine 30 mg/m 2 produced a partial response (PR) rate of 24% and an improvement in general physical symptoms in 41% of patients. 15 In a dose-finding study, Delord and colleagues observed that the coadministration of gemcitabine and vinorelbine did not enhance the toxicity profile of either drug in patients with advanced, previously treated malignancies. Moreover, this regimen demonstrated activity in a pretreated patient with MPM. 27 On the basis of this background, the objective of the current study was to assess the antitumor activity and toxicity of the combination of gemcitabine and vinorelbine in a population of pemetrexed-pretreated patients with MPM. MATERIALS AND METHODS Patient Selection Patients were eligible for this trial if they had histologically confirmed MPM that was not amenable to curative surgery and that was relapsing or progressing after 1 prior pemetrexed-based chemotherapy regimen. Eligibility criteria included age >18 years, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2, and an estimated life expectancy 12 weeks. Adequate organ function was required along with an absolute neutrophil count /L, platelets /L, hemoglobin 9 g/dl, bilirubin 1.5 times the upper limit of normal, aspartate and alanine transferase levels 3 times the upper limit of normal, and creatinine <2.0 mg/dl. Patients who were receiving palliative radiation therapy for painful lesions were allowed to enter the trial provided the patient had measurable disease outside the irradiated site. Previous treatment without pemetrexed-based chemotherapy, documented brain metastases, serious comorbidities, or other malignancies were not allowed. Written, informed consent was obtained from each patient before beginning treatment. Treatment Patients received gemcitabine at the dose of 1000 mg/m 2 intravenously as a 30-minute infusion followed by vinorelbine administered as a bolus infusion at the dose of 25 mg/m 2. Both drugs were given on Days 1 and 8 every 3 weeks. Standard antiemetic prophylaxis with intravenous metoclopramide was used before chemotherapy. Treatment was administered on an outpatient basis. Patients who demonstrated no disease progression continued treatment for a maximum of 6 cycles or until the withdrawal criteria were met. Dose adjustments at the start of a subsequent cycle of therapy were based on hematologic and nonhematologic toxicity observed during the preced-

3 Gemcitabine-Vinorelbine in MPM Patients/Zucali et al ing course. Any patient who required a dose reduction continued to receive a reduced dose for the remainder of the study. The administration of the next cycle was delayed in the case of: 1) an absolute neutrophil count of < /L and/or a platelet count of < /L; 2) any grade 3 or 4 nonhematologic toxicity (except for nausea/vomiting) that did not resolve to grade 1 or less; or 3) an ECOG PS >2. If these toxicities had not resolved by Day 28, then the dose was reduced for the next cycle at 75% of the previous dose level. No other systemic anticancer therapies were permitted. Patients were allowed supportive care measures and symptomatic treatment for any drug-related toxicity. Patient Assessment Baseline assessment included a complete medical history, physical examination, and complete blood count and chemistries. A chest and abdomen computed tomography (CT) scan was obtained at baseline. Patients were staged according to the International Mesothelioma Interest Group Tumor, Lymph Node, Metastasis (TNM) staging system. 28 Best tumor response was evaluated according to validated hybrid unidimensional and bidimensional criteria. 2 No confirmatory scans were conducted on patients who exhibited a PR or stable disease (SD). Treatment toxicity was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0 grading system. 29 Dose intensity (DI) was assessed separately for gemcitabine and vinorelbine in patients who received at least 2 cycles of chemotherapy as the median dose in milligrams per square meter per week. The percentage of planned DI delivered for both drugs also was calculated and reported as the relative DI (RDI). After completion of the study treatment, patients were evaluated every 2 months with chest and abdomen CT scans until disease progression. Patients also were followed for survival until death or last contact if they remained alive. Study Design and Statistical Analysis This study was planned as a single-institution Phase II trial. Patients were enrolled prospectively. The sample size of the trial was calculated according to the Simon 2-stage design, 30 with a type I and II error of <10% each, to differentiate between an RR of 10% and a response of 30%. According to this model, initial analysis was planned after 14 patients had been treated, and there was further accrual to a total of 25 patients if at least 1 objective response was observed in the first 14 patients. The planned accrual period was 24 months. The primary endpoints of the study were tumor RR and tolerability; secondary endpoints included TTP and OS. TTP was defined as time from study entry (first day of study treatment) until the time of patient progression (as demonstrated on radiologic or clinical examination) or death from any cause. Patients without any evidence of progressive disease were censored at the date of the last follow-up. OS was calculated as the time from study entry until death from any cause; patients who were alive at the date of last follow-up were censored at that date. The Kaplan-Meier method was used to calculate actuarial survival and follow-up. 31,32 Survival rates were analyzed according to the following variables: age (<70 years vs 70 years), ECOG PS (0 vs 1 vs 2), histology (epithelial vs nonepithelial), European Organization for Research and Treatment of Cancer (EORTC) prognostic score (good score vs poor score), 33 response to previous pemetrexed-based chemotherapy (PR or SD vs progressive disease), and TTP on previous pemetrexed-based chemotherapy (<6 months vs 6 months). The impact of these variables on TTP and OS was evaluated by using the Gehan Wilcoxon test. 34 Statistical analyses were performed by using the software package Stata 10 (STATA Corp, College Station, Tex). RESULTS Patients Characteristics Between January 2004 and September 2006, 30 consecutive patients who progressed after pemetrexedbased chemotherapy were enrolled. Their characteristics are listed in Table 1. There were 22 men and 8 women. The median age was 66 years (range, years). Most patients had a PS 1 (83%), an epithelial histologic subtype (70%), and a poor EORTC prognostic score (73%). Twenty-five patients (84%) had chest involvement only, whereas the remaining patients also had extrathoracic tumor sites. All patients had previously received a pemetrexed-based chemotherapy, and a PR and SD were reported in 6 patients (20%) and 15 patients (50%), respectively. Four patients (13%) had previously received pemetrexed as single agent, and 26 patients (87%) had received it in combination with a platinum agent, including cisplatin in 1 patient and carboplatin in 25 patients. Efficacy Twenty-nine of the 30 patients were evaluated for response, and 1 refused further treatment after 1

4 1558 CANCER April 1, 2008 / Volume 112 / Number 7 TABLE 1 Patient Characteristics Characteristics No. of patients (N 5 30) % Age, y Median 66 Range Sex Men Women 8 27 ECOG performance status EORTC prognostic score Good 8 27 Poor Histologic subtype Epithelial Sarcomatoid 2 7 Mixed cell 5 16 Unspecified 2 7 Previous treatment Pemetrexed 4 13 Pemetrexed/carboplatin Pemetrexed/cisplatin 1 3 Response to prior P-ChT CR 0 0 PR 6 20 SD PD 9 30 Median time of previous P-ChT response (range), mo PR 8.7 (7 10.7) SD 9 (4 19.8) ECOG indicates Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; P-ChT, pemetrexed-based chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. cycle and was not reassessed. According to an intention-to-treat analysis, 3 patients had a PR (10%; 95% confidence interval [CI], %), 10 patients had SD (33.3%; 95% CI, %) and 17 patients had progressive disease (56.7%; 95% CI, %). No complete responses were observed. The disease control rate (PR and SD for at least 6 weeks) was 43.3% (95% CI, %). Table 2 summarizes the outcome of the study population according to clinical characteristics. With a median follow-up of 10.8 months (95% CI, months) for all patients and 14.2 months (95% CI, months) for the patients who remained alive, 21 patients died and 9 were still alive. The median TTP was 2.8 months (range, months), and the median OS was 10.9 months (range months) (Fig. 1). Progression-free survival (PFS) rates at 3 months, 4 TABLE 2 Outcome of the Study Population According to Clinical Characteristics Characteristic No. of patients (%) TTP, mo OS, mo Median P Median P Histology Epithelial 21 (70) Nonepithelial 9 (30) ECOG performance status 0 9 (30) (53) (17) EORTC score Good 8 (27) Poor 22 (73) Age, y <70 21 (70) (30) TTP of previous treatment, mo 6 19 (63) <6 11 (37) Response to previous treatment PR and SD 21 (70) PD 9 (30) TTP indicates time to progression; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for Research and Treatment of Cancer; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. months, and 6 months were 44.8% (95% CI, %), 44.8% (95% CI, %), and 31% (95% CI, %), respectively. Treatment Delivery and Toxicity In total, 111 cycles of chemotherapy were delivered, and dose reductions occurred in 19 cycles (17% of all cycles). Patients received a median of 3 cycles of treatment (range, 1 6 cycles). Twenty-five patients (83%) received 2 or more cycles; in these patients, the median delivered DI was mg/m 2 per week for vinorelbine (RDI, 82.4%) and mg/m 2 per week for gemcitabine (RDI, 87.5%). Treatment generally was tolerated well. Hematologic toxicity was the most frequently reported side effect (Table 3), with grade 3 or 4 neutropenia observed in 3 patients (10%). No episodes of febrile neutropenia were reported. Nonhematologic toxicity generally was mild (Table 3). One death occurred during the treatment because of pneumonitis (without neutropenia) in a patient with SD who previously underwent extrapleural pneumonectomy. At the end of chemotherapy, among 13 patients achieving disease control, ECOG PS was stable in 9 patients, improved in 2 and worsened in 2.

5 Gemcitabine-Vinorelbine in MPM Patients/Zucali et al TABLE 3 Hematologic and Nonhematologic Toxicity by Patient (N 5 30)* No. of patients Toxicity Grade 1 Grade 2 Grade 3 Grade 4 Grade 3 4, % Neutropenia Anemia Thrombocytopenia Fatigue Nausea/vomiting Constipation Diarrhea Stomatitis Conjunctivitis Fever * Other toxicities that were reported as rare events included grade 2 hepatotoxicity (1 patient) and grade 2 peripheral neurotoxicity (1 patient). FIGURE 1. Survival curves. TTP indicates time to progression; OS, overall survival. DISCUSSION Second-line chemotherapy is being used increasingly in MPM, because patients who achieve a clinical benefit from first-line chemotherapy frequently still are healthy at the time of disease progression. However, to date, the role of second-line chemotherapy in MPM has not been proven, and few data are available to select effective drugs. In particular, prospective trials of second-line chemotherapy in pemetrexedpretreated patients with MPM are lacking (Table 4). In a retrospective analysis of patients who were treated in the Phase III pemetrexed trial, approximately 42% of all patients received some form of PSC. This group of patients had a significantly prolonged survival. However, because PSC was not randomized, it is impossible to know whether the reduced risk of death was associated with PSC or whether patients who had prolonged survival were able to receive more PSC. 21 In fact, the crucial point is to distinguish between the clinical/radiologic stability caused by treatment effect and the natural history of disease. To our knowledge, only 2 randomized studies have demonstrated that chemotherapy may be better than BSC in patients with MPM. 11,35 In particular, vinorelbine plus BSC in the first-line setting produced an improvement in terms of OS compared with BSC alone, although the difference was not statistically significant, 35 whereas pemetrexed in the second-line setting provided clinical benefit with a statistically significant improvement in terms of TTP, but not in terms of OS. 11 In the current study, we tested vinorelbine combined with gemcitabine in a population of patients who progressed after receiving pemetrexed-based chemotherapy. Hematologic and nonhematologic toxicities were mild. Grade 3 and 4 neutropenia was observed as the main toxicity in 3 patients (12.5%). One death occurred during the treatment because of pneumonitis (without neutropenia) in a patient with SD who previously underwent extrapleural pneumonectomy. The low rate of reduced cycles and the high median delivered DI of both study drugs provided evidence of good tolerability of this regimen in this group of patients. Although quality of life was not evaluated in our study, we observed that ECOG PS remained roughly stable in most patients who achieved disease control. Overall, the RR (10%), disease control rate (43.3%), TTP (2.8 months), and OS (10.9 months) were in line with data reported in the literature (Table 5). It is noteworthy that the proportion of patients who had SD was considerable. Emerging data suggest that the survival outcomes faithfully reflect the drugs activity and should represent the best treatment endpoints in patients with MPM in view of the marked difficulty in assessing radiologic response. 36,37 Fennell et al. demonstrated that the radiologic response did not appear to be

6 1560 CANCER April 1, 2008 / Volume 112 / Number 7 TABLE 4 Studies of Second-line Chemotherapy in Patients With Malignant Pleural Mesothelioma Reference Regimen No. RR, % DCR, % mttp, mo msv, mo Pemetrexed-naive patients Giaccone ZD0437 (platinum analog) 47 12* Porta Raltitrexed 1 oxaliplatin Fizazi Raltitrexed 1 oxaliplatin wks 44 wks Sorensen Pemetrexed NR 147 d 294 d Sorensen Pemetrexed 1 carboplatin NR 222 d 258 d Jassem y Pemetrexed NR Fennell Irinotecan 1 cisplatin 1 mitomycin Pemetrexed-pretreated patients Serke Oxaliplatin1/2gemcitabine 18 22* 50 NR NR RR indicates response rate; DCR, disease control rate; mttp, median time to progression; msv, median survival; NR, not reported; 1/2, with or without, d, day. * Responses were reported as minor responses. y Randomized trial of pemetrexed versus best supportive care (data reported for pemetrexed arm only); irinotecan (Campto; Pfizer, Capelle aan den IJssel, the Netherlands). correlated with survival improvement. 38 A recent overview of the EORTC Lung Cancer Group pointed out that replacement of the RR by TTP as the primary endpoint would allow a better selection of clinically active drugs. 39 In our study, PFS was not designed as the primary endpoint. However, considering the 3 EORTC categories (although they were not derived from second-line studies), our regimen demonstrated an activity between insufficient and moderate. Accordingly, the PFS rate at 6 months was 31%, which is in the range of regimens with poor activity in the first-line setting, but it could be revalued in view of the second-line setting of our combination and the characteristics of our population. The majority of our population (73%) had a poor EORTC prognostic score, which is expected to be associated with a shorter survival. 33 Indeed, stratifying our data for EORTC score, patients who had good scores had a significantly improved OS compared with patients who had poor scores (Table 2). Similarly, OS was significantly longer in patients who had a good ECOG PS. In addition, as reported in randomized trials of second-line therapy in patients with small cell and nonsmall cell lung cancer, in our MPM population, disease progression during firstline therapy and a shorter interval from completion of first-line therapy were correlated with shorter TTP and OS after second-line treatment (Table 2). In conclusion, the results from this study suggest the feasibility of giving second-line chemotherapy to patients with MPM. Unfortunately, the results remain modest, although chemotherapy could be offered to these patients for palliation. However, MPM should be considered an ideal field in which to test new chemotherapy agents as well as new therapeutic strategies, including antiangiogenic compounds, small molecules or monoclonal antibodies that target different molecular pathways, and gene therapy. 40 Although it has been demonstrated that targeted therapy with epidermal growth factor receptor and platelet-derived growth factor receptor inhibitors and antiangiogenic drugs is ineffective in unselected patients, an improvement in our knowledge of the major molecular pathways involved in MPM should define proper targets for the systemic treatment of this disease. Reinduction of apoptosis by manipulating its critical control points (tumor necrosis factor 10 receptor, histone deacetylases, and the proteasome), the inhibition of hepatocyte growth factor and its receptor c-met, the inhibition of angiogenesis, and evaluating the synergism between chemotherapy and targeted therapy all are interesting fields in which to develop new, effective treatments. The role of second-line treatment in MPM needs to be evaluated in prospective trials on large series of patients stratified according to previous treatment, prognostic factors, and biologic features. REFERENCES 1. Peto J, Decarli A, La Vecchia C, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79: Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21: Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21: Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24:

7 Gemcitabine-Vinorelbine in MPM Patients/Zucali et al Giaccone G, O Brien ME, Byrne MJ, Bard M, Kaukel E, Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer. 2002;38:S19 S Porta C, Zimatore M, Bonomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005;48: Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003;21: Fennell DA, Steele JP, Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007;109: Vogelzang NJ. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma? J Clin Oncol. 1999;17: Sorensen JB, Sundstrom S, Perrell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma (MPM) after platinum-based first-line treatment. J Thorac Oncol. 2007;2: Jassem J, Ramlau R, Santoro A, et al. A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (pts) with advanced pleural mesothelioma (MPM) [abstract]. Ann Oncol. 2006;17:214a. 12. Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2003;21: Kindler HL, Van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002;29: Van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999;85: Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18: Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17: Nowak A, Byrne M, Williamson R. Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87: Van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86: Favaretto AG, Aversa SML, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma. A multicentric phase II study. Cancer. 2003;97: Bischoff HG, Manegold C, Knopp M, Blatter J, Drings P. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol. 1998;17:464a. Abstract Manegold C, Symanowski J, Gatzemeier U, et al. Secondline (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16: Mbidde EK, Harland SJ, Calvert AH, Smith IE. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol. 1986; 18: Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. Clin Oncol. 1990;8: Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol. 1990;27: Schutte W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer. 2003;4: Serke M, Xanthopoulos A, Bauer T. Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/ gemcitabine [abstract]. Ann Oncol. 2006;17(suppl 9):231a. 27. Delord JP, Raymond E, Chaouche M, et al. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol. 2000;11: Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest. 1995;108: National Cancer Institute. Common Toxicity Criteria manual, version 3.0: July 16, Available from: cancer.gov/reporting/ctc.html. Accessed July Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10: Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53: Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17: Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16: Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly censored data. Biometrika. 1965;52: Muers M, Fisher P, Snee M, et al. A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: first results of the Medical Research Council (MRC)/British Thoracic Society (BTS) MS01 trial. J Clin Oncol, 1997 ASCO Annual Meeting Proceedings, Part ;25:18S(June 20 suppl). Abstract LBA Korn EL, Arbuck SG, Pluda JM, Simon R, Kaplan RS, Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001;19: Van Glabbeke M, Verweij J, Judson I, Nielsen OS;EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38: Fennell D, Steele J, Sheaff M, et al. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer. 2005;49:S220. Abstract P Francart J, Legrand C, Sylvester R, et al. Progression-free survival rate as primary endpoint for phase II cancer clinical trials: application to mesothelioma. The EORTC Lung Cancer Group. J Clin Oncol. 2006;24: Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006;42:

Activity of pemetrexed in thoracic malignancies

Activity of pemetrexed in thoracic malignancies Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is

More information

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10

NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10 Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage

More information

Second-Line Chemotherapy

Second-Line Chemotherapy 40 Second-Line Chemotherapy Nick Pavlakis and Nicholas J. Vogelzang Chemotherapy trials for malignant pleural mesothelioma have almost exclusively focused on chemotherapy-naive patients. Until 2000, the

More information

J Clin Oncol 24:3007-3012. 2006 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 24:3007-3012. 2006 by American Society of Clinical Oncology INTRODUCTION VOLUME 24 NUMBER 19 JULY 1 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Progression-Free Survival Rate As Primary End Point for Phase II Cancer Clinical Trials: Application to Mesothelioma

More information

London Cancer. Mesothelioma Lung Protocols

London Cancer. Mesothelioma Lung Protocols London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT

More information

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009

the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy

More information

Report on New Patented Drugs - Alimta

Report on New Patented Drugs - Alimta Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive

More information

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai

Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s

More information

Kasr El-Aini Center of Clinical Oncology, Faculty of medicine, 2 Chest Department, Faculty of medicine, Cairo University, egypt

Kasr El-Aini Center of Clinical Oncology, Faculty of medicine, 2 Chest Department, Faculty of medicine, Cairo University, egypt Kasr El-aini J. Clin. Oncol. nucl. med. vol., no. 3-4, Jul.-oct. 006:4-47 NEMROCK Original Article Phase II Trial of Cisplatin and Vinorelbine as First-line Therapy in Malignant Pleural Mesothelioma Salah

More information

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study

Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,

More information

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy Lung Cancer International Volume 2015, Article ID 590148, 7 pages http://dx.doi.org/10.1155/2015/590148 Research Article Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS

More information

Malignant Mesothelioma State of the Art

Malignant Mesothelioma State of the Art Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG

More information

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status

Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status Available online at www.sciencedirect.com Journal of the Chinese Medical Association 74 (2011) 209e214 Original Article Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with

More information

Efficacy and Safety of First- or Second-line Irinotecan, Cisplatin, and Mitomycin in Mesothelioma

Efficacy and Safety of First- or Second-line Irinotecan, Cisplatin, and Mitomycin in Mesothelioma 93 Efficacy and Safety of First- or Second-line Irinotecan, Cisplatin, and Mitomycin in Mesothelioma Dean A. Fennell, MD 1 Jeremy P. C. Steele, MD 1 Jonathan Shamash, MD 1 Marie T. Evans, MD 1 Paula Wells,

More information

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010

Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015

More information

Mesothelioma. Malignant Pleural Mesothelioma

Mesothelioma. Malignant Pleural Mesothelioma Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency

More information

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam

Mesothelioma 2014. Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Mesothelioma 2014 Paul Baas Department of Thoracic Oncology The Netherlands Cancer Institute Amsterdam Disclosures Grants from Pfizer and Roche Advisor for MSD and Verastem Once upon a time. http://amlbenzene.net/diseases-asbestos.htm

More information

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single

More information

Emerging Drug List GEFITINIB

Emerging Drug List GEFITINIB Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:

More information

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group

REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory

More information

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012

Summary ID# 13095. Clinical Study Summary: Study H3E-EW-B012 Page 1 Summary ID# 13095 Clinical Study Summary: Study H3E-EW-B012 First-line Treatment of Non-Small Cell Lung Cancer under Routine Conditions: Observational Study on Overall Survival Date summary electronically

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT

More information

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007

National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007 Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

MALIGNANT MESOTHELIOMA is an aggressive

MALIGNANT MESOTHELIOMA is an aggressive Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study By M.J. Byrne, J.A. Davidson, A.W. Musk, J. Dewar, G. van Hazel, M. Buck, N.H. de Klerk, and B.W.S. Robinson Purpose: We

More information

Post-operative intrapleural chemotherapy for mesothelioma

Post-operative intrapleural chemotherapy for mesothelioma Post-operative intrapleural chemotherapy for mesothelioma Robert Kratzke, MD John Skoglund Chair for Lung Cancer Research Section of Heme-Onc-Transplant University of Minnesota Medical School Efficacy

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

SMALL CELL LUNG CANCER

SMALL CELL LUNG CANCER Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Endpoint Selection in Phase II Oncology trials

Endpoint Selection in Phase II Oncology trials Endpoint Selection in Phase II Oncology trials Anastasia Ivanova Department of Biostatistics UNC at Chapel Hill aivanova@bios.unc.edu Primary endpoints in Phase II trials Recently looked at journal articles

More information

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004

Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004 Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer

More information

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)

Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade

More information

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide

More information

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)

Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing) Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the

More information

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany

Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee

More information

Summary of treatment benefits

Summary of treatment benefits Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell

More information

Management of Platinum-Sensitive Recurrent Ovarian Cancer

Management of Platinum-Sensitive Recurrent Ovarian Cancer Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.

More information

Evaluation of asbestos-exposure, clinical diagnosis and treatment of MPM

Evaluation of asbestos-exposure, clinical diagnosis and treatment of MPM Evaluation of asbestos-exposure, clinical diagnosis and treatment of MPM Aija Knuuttila, MD, PhD Dept. of Pulmonary Medicine Helsinki University Central Hospital, Finland 15.11.2007 Malignant pleural mesothelioma

More information

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy

Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Eur Respir J 2012; 40: 185 189 DOI: 10.1183/09031936.00153611 CopyrightßERS 2012 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy Ronald A.M. Damhuis*, Caroline

More information

MALIGNANT PLEURAL mesothelioma (MPM) is a locally

MALIGNANT PLEURAL mesothelioma (MPM) is a locally Phase III Study of Pemetrexed in Combination With Versus Alone in Patients With Malignant Pleural Mesothelioma By Nicholas J. Vogelzang, James J. Rusthoven, James Symanowski, Claude Denham, E. Kaukel,

More information

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited

More information

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)

West of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility

More information

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 1, March: 61-70, 2007 Assessment of Survival and Clinical Benefit in Malignant Pleural Mesothelioma (MPM) Patients Treated with Gemcitabine and Carboplatin

More information

SAKK Lung Cancer Group. Current activities and future projects

SAKK Lung Cancer Group. Current activities and future projects SAKK Lung Cancer Group Current activities and future projects SAKK Lung Cancer Group Open group of physicians interested in lung cancer Mostly Medical Oncologists, but also Thoracic Surgeons Radiation

More information

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4

Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4 Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.

More information

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1

EVALUATION/PRIORITIZATION CRITERIA: C, L, R, S *to meet requirement 1 COMPENDIA TRANSPARENCY TRACKING FORM DATE: MAY 2015 PACKET: 111 DRUG: INDICATION: Vinorelbine Tartrate Malignant pleural mesothelioma COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize

More information

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute

Clinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,

More information

Introduction Objective Methods Results Conclusion

Introduction Objective Methods Results Conclusion Introduction Objective Methods Results Conclusion 2 Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma a rare cancer associated with long latency period (i.e. 20 to 40 years),

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and

More information

Out-Patient Chemotherapy for Lung Cancer

Out-Patient Chemotherapy for Lung Cancer Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent

More information

Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors

Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors Preliminary Results from a Phase 2 Study of ARQ 197 in Patients with Microphthalmia Transcription Factor Family (MiT) Associated Tumors John Goldberg 1 *, George Demetri 2, Edwin Choy 3, Lee Rosen 4, Alberto

More information

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness

More information

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating?

Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating? Dr Peter Briggs Medical Oncologist Lung Cancer & Mesothelioma: is it worth treating? GOALS OF CANCER THERAPY CURE Good chance Medium chance Low chance PALLIATION Life prolonging Symptomatic improvement

More information

Management of mesothelioma

Management of mesothelioma Management of mesothelioma Jan.vanmeerbeeck@ugent.be Amsterdam, March 6, 2010 1 management Palliation Symptomatic care Pain Breathlessness Radiotherapy Chemotherapy Surgery Radical (intention to cure)

More information

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases

IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain

More information

New Treatment Options for Breast Cancer

New Treatment Options for Breast Cancer New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of

More information

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509. Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.

More information

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents

January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for

More information

J Clin Oncol 26:3567-3572. 2008 by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 26:3567-3572. 2008 by American Society of Clinical Oncology INTRODUCTION VOLUME 26 NUMBER 21 JULY 20 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pemetrexed Plus Gemcitabine As First-Line Chemotherapy for Patients With Peritoneal Mesothelioma: Final Report

More information

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group

Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Malignant Pleural Mesothelioma in Singapore

Malignant Pleural Mesothelioma in Singapore RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and

More information

Malignant pleural mesothelioma (MPM) is a malignancy

Malignant pleural mesothelioma (MPM) is a malignancy Original Article Is Radiotherapy Useful for Treating Pain in Mesothelioma? A Phase II Trial Nicholas MacLeod, FRCR,* Anthony Chalmers, PhD, Noelle O Rourke, MD, Karen Moore, BSc, Jonathan Sheridan, FRCR,

More information

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline

Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:

More information

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011

Metastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011 Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare

More information

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate

Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate + Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN

More information

Lung Cancer and Mesothelioma

Lung Cancer and Mesothelioma Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant

More information

SECOND-LINE CHEMOTHERAPY in advanced non

SECOND-LINE CHEMOTHERAPY in advanced non Gemcitabine as Second-Line Treatment for Advanced Non Small-Cell Lung Cancer: A Phase II Trial By Lucio Crinò, Anna Maria Mosconi, Giorgio Scagliotti, Giovanni Selvaggi, Silvia Novello, Massimo Rinaldi,

More information

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist

Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the

More information

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer?

Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Original Article Is there a positive effect of participation on a clinical trial for patients with advanced nonsmall cell lung cancer? Rajappa S, Gundeti S, Uppalapati S, Jiwatani S, Abhyankar A, Pal C,

More information

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience

Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience Bearz et al. BMC Research Notes 2012, 5:482 RESEARCH ARTICLE Open Access Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience Alessandra Bearz 1,9*, Renato Talamini 2,

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Malignant pleural mesothelioma P/D vs. EPP

Malignant pleural mesothelioma P/D vs. EPP 3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy

More information

The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992)

The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992) European Journal of Cancer 39(2003) 353 357 www.ejconline.com The activity of raltitrexed (Tomudex 1 ) in malignant pleural mesothelioma: an EORTC phase II study (08992) P. Baas a, *, A. Ardizzoni b, F.

More information

Understanding Clinical Trials

Understanding Clinical Trials Understanding Clinical Trials HR =.6 (CI :.51.7) p

More information

Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey

Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: An institutional experience in Turkey JBUON 2014; 19(1): 164-170 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Clinical characteristics, treatment and survival outcomes in malignant

More information

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20

Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012

Overview of Ovarian Cancer. Dr. Sinead Noonan 13/03/2012 Overview of Ovarian Cancer Dr. Sinead Noonan 13/03/2012 Ovarian Cancer 4 th most common cause of cancer death in women 15,000 deaths/year in the US Each year 300 new cases in Ireland 80% epithelial cell

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

ARTICLE IN PRESS. European Journal of Radiology xxx (2009) xxx xxx. Contents lists available at ScienceDirect. European Journal of Radiology

ARTICLE IN PRESS. European Journal of Radiology xxx (2009) xxx xxx. Contents lists available at ScienceDirect. European Journal of Radiology European Journal of Radiology xxx (2009) xxx xxx Contents lists available at ScienceDirect European Journal of Radiology journal homepage: www.elsevier.com/locate/ejrad Three-dimensional evaluation of

More information

New Targets and Treatments for Follicular Lymphoma. Disclosures

New Targets and Treatments for Follicular Lymphoma. Disclosures Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:

More information

Clinical Study Report

Clinical Study Report An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,

More information

People Living with Cancer

People Living with Cancer Patient Guide ASCOInformation for People Living with Cancer ADVANCED LUNG CANCER TREATMENT Recommendations of the American Society of Clinical Oncology Welcome The American Society of Clinical Oncology

More information

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)

Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,

More information

Malignant Mesothelioma: an Update

Malignant Mesothelioma: an Update Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers

More information

Malignant Pleural Mesothelioma

Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma Joseph Friedberg, MD Hedy Lee Kindler, MD Lee Krug, MD Kenneth Rosenzweig, MD Epidemiology of Mesothelioma Incidence: 2,500 3,000 cases year in the US 5,000 cases per year

More information

Redacted Protocol for Journal of Clinical Oncology

Redacted Protocol for Journal of Clinical Oncology Redacted PARAMOUNT Clinical Protocol Page 1 Redacted Protocol for Journal of Clinical Oncology Protocol S124(b) (PARAMOUNT) A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance plus Best Supportive

More information

Come è cambiata la storia naturale della malattia

Come è cambiata la storia naturale della malattia Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal

More information

Management of low grade glioma s: update on recent trials

Management of low grade glioma s: update on recent trials Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,

More information

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases

Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases Role of taxanes in the treatment of advanced NHL patients: A randomized study of 87 cases R. Shraddha, P.N. Pandit Radium Institute, Patna Medical College and Hospital, Patna, India Abstract NHL is a highly

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

بسم هللا الرحمن الرحيم

بسم هللا الرحمن الرحيم بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma

More information

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:

Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction: Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer

More information

Chapter 7: Lung Cancer

Chapter 7: Lung Cancer Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin

More information

What is the reference cytotoxic regimen in advanced gastric cancer?

What is the reference cytotoxic regimen in advanced gastric cancer? What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.

More information